Calidi Loss Down 23 Percent in Fiscal Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Source: Fool
Financial Performance: Calidi Biotherapeutics reported a net loss of $5.7 million for Q2 2025, slightly worse than analyst expectations, while cash reserves decreased significantly to $5.3 million, highlighting ongoing funding challenges despite narrowing losses and operational improvements.
Product Development Progress: The company made advancements with its RedTail platform for cancer therapy, secured Fast Track Designation for its CLD-201 immunotherapy, and aims for an IND filing for CLD-401 by the end of 2026, although no revenue was recorded during this period.
Analyst Views on CLDI
About CLDI
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
